US › Healthcare

Precision BioSciences Inc (DTIL)

US · Healthcare · Biotechnology

$7.28+3.12%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$10.8M
Revenue YoY
+37272.4%
Net profit
$-18.4M
Profit YoY
+10.3%
EPS
$-0.75
EPS estimate
$-0.81
Net margin
-170.2%

EPS came in at -0.75 against a street estimate of -0.81 — a beat of 7.4%.

Key statistics

Market cap
$180.4M
Forward P/E
11.8
P/B
2.31
Book value
$2.95
EPS (TTM)
$-2.17
52-week high
$9.62
52-week low
$3.53
50-day MA
$7.34
200-day MA
$6.03
Beta
1.25

Analyst view

Analysts rate Precision BioSciences Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $29.60.

Shareholding

Insiders
6.44%
Institutions
64.04%

Largest institutional holders

FundStake
Octagon Capital Advisors LP8.67%
Aberdeen Group PLC8.64%
Empery Asset Management, LP7.63%
Bleichroeder LP6.44%
BOOTHBAY FUND MANAGEMENT, LLC4.13%
Driehaus Capital Management LLC3.86%
Lynx1 Capital Management, LP3.82%
Vanguard Capital Management, LLC3.53%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Precision BioSciences Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.